Scientists develop sugar treatment for the most aggressive form of brain cancer

Scientists have developed a potential new treatment for glioblastoma, the most aggressive form of brain cancer, using sugar-based nanoparticles. The research was led by scientists at Oregon State University in the United States and published in the Journal of Controlled Release. Glioblastoma has a survival rate of less than 30% after two years, making it one of the deadliest cancers. The study addresses two major challenges in treating the disease: delivering therapeutic agents through the blood-brain barrier and ensuring these agents target tumors specifically. In experiments with mouse models, researchers loaded lipid-based nanoparticles with genetic material that promotes tumor suppression. They then coated these particles with a type of sugar called mannose, which is closely related to glucose, the body's primary energy source. According to the researchers, brain endothelial cells are covered with a transporter known as GLUT1, responsible for transporting glucose into the central nervous system. However, this transporter also recognizes mannose, allowing the nanoparticles to cross the blood-brain barrier. The study was directed by Oleh Taratula, Olena Taratula, and Yoon Tae Goo from the College of Pharmacy at Oregon State University. In a statement, Oleh Taratula explained that blood contains relatively high concentrations of glucose, and the nanoparticles compete with glucose for attention from GLUT1. To ensure the nanoparticles reach their destination, they need a surface densely coated with sugar, which represents the main innovation of the study. He added that chemically attaching mannose to cholesterol, a key structural component of the nanoparticles, improved surface coverage sixfold. Inside the nanoparticles is messenger RNA that allows the production of PTEN, a protein that fights tumors and is often lost in glioblastoma. To prevent the cargo from being altered, the team added a cationic derivative of cholesterol that protects the encapsulation of the mRNA. Olena Taratula noted that glioblastoma undergoes metabolic reprogramming and expresses GLUT1 at levels three times higher than normal brain tissue. As a result, the particles accumulate preferentially in tumor tissue after crossing the blood-brain barrier. She added that restoring PTEN expression in tumor cells restores growth control. Repeated administration of doses resulted in tumor reduction without detectable organ toxicity. The researchers emphasize that their work has shown promising results in early stages. However, they caution that the mannose-cholesterol nanoparticles still require years of safety and efficacy testing before reaching the market. Therefore, further research is needed to advance possible new treatments based on this approach. The development follows ongoing efforts to find more effective therapies for glioblastoma, which remains difficult to treat due to its rapid progression and resistance to conventional treatments. Researchers worldwide continue to explore innovative methods, including targeted drug delivery systems and gene therapy approaches, to improve patient outcomes. The findings highlight the potential of using biocompatible materials such as sugars and lipids to enhance drug delivery across biological barriers. This approach could open new avenues for treating not only glioblastoma but other diseases requiring precise targeting of specific tissues or organs. The study underscores the importance of interdisciplinary collaboration between pharmacologists, biochemists, and neuroscientists to develop novel therapeutic strategies. While the road to clinical application is long, the initial success in animal models offers hope for future advancements in cancer treatment. Researchers plan to conduct additional studies to refine the formulation and evaluate its effectiveness in larger animal models before proceeding to human trials. They remain optimistic about the potential impact of this technology on patients suffering from aggressive forms of cancer.